Page last updated: 2024-11-13

bananin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bananin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID59053860
CHEMBL ID4749450
SCHEMBL ID15466441
MeSH IDM0468700

Synonyms (8)

Synonym
AKOS016036756
SCHEMBL15466441
bananin
CS-0356439
HY-145113
CHEMBL4749450
665026-57-3
AKOS040758270

Research Excerpts

Overview

Bananins have a unique structural signature incorporating a trioxa-adamantane moiety covalently bound to a pyridoxal derivative.

ExcerptReferenceRelevance
"Bananins are a class of antiviral compounds with a unique structural signature incorporating a trioxa-adamantane moiety covalently bound to a pyridoxal derivative. "( The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus.
He, ML; Huang, JD; Jiang, JQ; Kesel, AJ; Kung, HF; Lin, YP; Lu, LY; Tanner, JA; Watt, RM; Wong, KL; Zheng, BJ; Zhou, J, 2005
)
2.08
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1717814Antiviral actvity against SARS-CoV GZ50 infected in Rhesus macaque FRhK-4 cells assessed as reduction in virus-induced cytopathic effect incubated for 24 to 48 hrs by phase-contrast microscopy2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1717815Cytotoxicity against Rhesus macaque FRhK-4 cells by MTT assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1718102Inhibition of SARS-CoV NSP13 helicase in presence of DT20Cy3 and ReleaseBHQ by FRET-based assay2020Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22
Druggable targets from coronaviruses for designing new antiviral drugs.
AID1717792Inhibition of SARS Coronavirus helicase pp1ab domain assessed as reduction in helicase activity using DT20Cy3/Release BHQ oligomers by FRET-based assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1717791Inhibition of SARS Coronavirus helicase pp1ab domain assessed as reduction in ATPase activity by phosphomolybdate-malachite green assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.93 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index123.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (75.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]